Registered title, quoted from ClinicalTrials.gov
ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Fourth Hospital of Hebei Medical University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07410611, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically confirmed newly diagnosed or treatment-naïve oligometastatic stage IV NSCLC (AJCC 9th edition) with ≤3 involved organs and ≤5 metastatic lesions. Regional lymph node involvement (regardless of number) is not counted as metastatic sites; non-regional lymph node involvement is classified as a metastatic lesion;
Inclusion criterion 2
No prior systemic anti-tumor therapy for advanced NSCLC, including standard chemotherapy, biologic therapy, targeted therapy, immunotherapy, or investigational drug treatment before starting the study drug. Patients who have received adjuvant or neoadjuvant therapy (chemotherapy and/or radiotherapy) are eligible if there has been no progression within 6 months after completion of such therapy;
Inclusion criterion 7
ECOG performance status 0-1;
Inclusion criterion 5
Presence of an EGFR sensitizing mutation (19Del or 21L858R);
Inclusion criterion 3
Hemoglobin (HB) ≥90 g/L;
Inclusion criterion 9
Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L;
Inclusion criterion 10
Platelet count (PLT) ≥100 × 10⁹/L;
Inclusion criterion 11
White blood cell count (WBC) ≥4.0 × 10⁹/L and ≤15 × 10⁹/L.
Inclusion criterion 12
AST and ALT ≤1.5 × ULN (≤5 × ULN if liver metastases are present);
Inclusion criterion 13
Alkaline phosphatase (ALP) ≤2.5 × ULN;
Inclusion criterion 14
Total bilirubin (TBiL) ≤1.5 × ULN;
Inclusion criterion 15
Serum creatinine (Cr) ≤1.5 × ULN and creatinine clearance (CrCL) ≥60 mL/min (Cockcroft-Gault formula);
Inclusion criterion 17
Activated partial thromboplastin time (APTT) ≤1.5 × ULN, and INR or PT ≤1.5 × ULN.
Inclusion criterion 18
Confirmed EGFR exon 20 insertion mutation or non-classical mutations such as L861Q, G719X, or S768I;
Exclusion criterion 2
At least one measurable lesion according to RECIST v1.1;
Inclusion criterion 4
Patients with symptomatic brain metastases, carcinomatous meningitis, or spinal cord compression, or imaging (CT or MRI) findings of brain or leptomeningeal disease at screening (except those with previously treated brain metastases who have been stable and without progression for ≥4 weeks before enrollment, and confirmed by brain MRI, CT, or venography to have no evidence of intracranial hemorrhage);
Exclusion criterion 4
Small cell lung cancer or non-small cell lung cancer mixed with histologic types such as small cell lung cancer or neuroendocrine carcinoma;
Exclusion criterion 1
Women of childbearing potential must agree to use effective contraception (e.g., intrauterine device, oral contraceptives, or condoms) during the study and for 6 months after study completion; a negative serum or urine pregnancy test within 7 days before enrollment is required, and the patient must not be breastfeeding. Male participants must agree to use contraception during the study and for 6 months afterward;
Inclusion criterion 19
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07410611, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age 18-75 years at the time of signing the informed consent form, both males and females are eligible;
- Histologically confirmed newly diagnosed or treatment-naïve oligometastatic stage IV NSCLC (AJCC 9th edition) with ≤3 involved organs and ≤5 metastatic lesions. Regional lymph node involvement (regardless of number) is not counted as metastatic sites; non-regional lymph node involvement is classified as a metastatic lesion;
- Presence of an EGFR sensitizing mutation (19Del or 21L858R);
- At least one measurable lesion according to RECIST v1.1;
- ECOG performance status 0-1;
- Life expectancy ≥12 weeks;
- No prior systemic anti-tumor therapy for advanced NSCLC, including standard chemotherapy, biologic therapy, targeted therapy, immunotherapy, or investigational drug treatment before starting the study drug. Patients who have received adjuvant or neoadjuvant therapy (chemotherapy and/or radiotherapy) are eligible if there has been no progression within 6 months after completion of such therapy;
- Adequate organ function (no transfusion, growth factor support, or medical correction within 14 days before screening):
Hematology:
- Hemoglobin (HB) ≥90 g/L;
- Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L;
- Platelet count (PLT) ≥100 × 10⁹/L;
- White blood cell count (WBC) ≥4.0 × 10⁹/L and ≤15 × 10⁹/L.
Blood biochemistry (no transfusion or albumin infusion within 14 days before screening):
- AST and ALT ≤1.5 × ULN (≤5 × ULN if liver metastases are present);
- Alkaline phosphatase (ALP) ≤2.5 × ULN;
- Total bilirubin (TBiL) ≤1.5 × ULN;
- Albumin (ALB) ≥30 g/L;
- Serum creatinine (Cr) ≤1.5 × ULN and creatinine clearance (CrCL) ≥60 mL/min (Cockcroft-Gault formula);
- Activated partial thromboplastin time (APTT) ≤1.5 × ULN, and INR or PT ≤1.5 × ULN.
- Women of childbearing potential must agree to use effective contraception (e.g., intrauterine device, oral contraceptives, or condoms) during the study and for 6 months after study completion; a negative serum or urine pregnancy test within 7 days before enrollment is required, and the patient must not be breastfeeding. Male participants must agree to use contraception during the study and for 6 months afterward;
- Voluntary participation in the study, provision of written informed consent, good compliance, and willingness to provide blood samples.
Exclusion Criteria:
- Small cell lung cancer or non-small cell lung cancer mixed with histologic types such as small cell lung cancer or neuroendocrine carcinoma;
- Confirmed EGFR exon 20 insertion mutation or non-classical mutations such as L861Q, G719X, or S768I;
- Prior systemic anti-tumor therapy for advanced/metastatic NSCLC (e.g., standard chemotherapy, targeted therapy, biologic therapy, immunotherapy, etc.);
- Patients with symptomatic brain metastases, carcinomatous meningitis, or spinal cord compression, or imaging (CT or MRI) findings of brain or leptomeningeal disease at screening (except those with previously treated brain metastases who have been stable and without progression for ≥4 weeks before enrollment, and confirmed by brain MRI, CT, or venography to have no evidence of intracranial hemorrhage);
- Known history of hypersensitivity to the active or inactive excipients of Befotertinib or to drugs with similar chemical structures or classes;
- Factors that significantly affect oral drug absorption, such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.;
- History of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonitis requiring steroid treatment;
- Any evidence of severe or uncontrolled systemic disease, including uncontrolled hypertension, diabetes, active bleeding, etc., that in the investigator's judgment would compromise patient participation or protocol compliance, or any active infection including uncontrolled hepatitis B, hepatitis C, or human immunodeficiency virus (HIV);
- QTc prolongation >470 ms or any clinically significant arrhythmia;
- Any condition that, in the investigator's judgment, would preclude participation in this study, including patients deemed unlikely to comply with study procedures, constraints, and requirements, or other situations at the investigator's discretion.
Quoted from ClinicalTrials.gov, NCT07410611, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07410611, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.